Name (Synonyms) | Correlation | |
---|---|---|
drug1236 | Hemanext One Wiki | 0.71 |
drug1338 | Hyperbaric oxygen therapy Wiki | 0.71 |
drug2171 | Placebo- 1.00 mg/kg Wiki | 0.71 |
drug2129 | Placebo 0.20 mg + 2.00 mg/kg Wiki | 0.71 |
drug929 | Drug: NA-831 - 0.10 mg/kg Wiki | 0.71 |
drug925 | Drug: GS-5734 - 1.00 mg/kg Wiki | 0.71 |
drug932 | Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) Wiki | 0.71 |
drug2170 | Placebo- 0.20 mg/kg Wiki | 0.71 |
drug2128 | Placebo 0.10 mg + 1.00 mg/kg Wiki | 0.71 |
drug2172 | Placebo- 2.00 mg/kg Wiki | 0.71 |
drug930 | Drug: NA-831 - 0.20 mg/kg Wiki | 0.71 |
drug2169 | Placebo- 0.10 mg/kg Wiki | 0.71 |
drug933 | Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) Wiki | 0.71 |
drug1924 | Normobaric oxygen therapy Wiki | 0.71 |
drug926 | Drug: GS-5734 - 2.00 mg/kg Wiki | 0.71 |
drug3208 | blood samples Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D009410 | Nerve Degeneration NIH | 1.00 |
D004660 | Encephalitis NIH | 0.71 |
D012141 | Respiratory Tract Infections NIH | 0.14 |
D003141 | Communicable Diseases NIH | 0.11 |
D014777 | Virus Diseases NIH | 0.08 |
D007239 | Infection NIH | 0.07 |
D013577 | Syndrome NIH | 0.07 |
D011014 | Pneumonia NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002383 | Encephalitis HPO | 0.71 |
HP:0011947 | Respiratory tract infection HPO | 0.14 |
HP:0002090 | Pneumonia HPO | 0.04 |
There are 2 clinical trials
Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache). Since neurotropism is a common feature of coronavirus infection in animals, the investigators examine if indirect signs of CNS lesion are observed in association with severe Covid-19 infection.
Description: Change of neurofilament light chain (NFL) (pg/ml) level between first day of hospitalisation and one week; and change of GFAP (pg/ml) level between first day of hospitalisation and one week.
Measure: Change of neurodegeneration markers level Time: Level of neurofilament light chain (NFL) is dosed at inclusion (day 0) and week 1. Level of GFAP is dosed at inclusion (day 0) and week 1 (day 7).The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.
Description: AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0
Measure: Proportion of Participants Experiencing any Treatment-Emergent Adverse Events Time: First dose date up to Day 30 Follow-up AssessmentDescription: This will be assessed at various time points by clinical laboratory tests and vital signs.
Measure: Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities Time: First dose date up to Day 30 Follow-up AssessmentDescription: Monitoring of the levels of drugs in subject sera at various time points to elucidate the maximum concentration (Cmax) of NA-831 and GS-5734 in human serum.
Measure: Maximum Concentration (Cmax) - Pharmacokinetic Assessment Time: 7 daysDescription: Monitoring of the levels of drugs in subject sera at various time points to elucidate the time to maximum concentration (Tmax) of NA-831 and GS-5734 in human serum
Measure: Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment Time: 7 daysDescription: Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve from time of administration to the last measurable of NA-831 and GS-5734
Measure: AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment Time: 7 daysDescription: Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve extrapolated to infinity (AUC0-∞) of NA-831 and GS-5734
Measure: Area Under the Curve Extrapolated to Infinity (AUC0-∞) Time: 7 daysDescription: Monitoring of the levels of drugs in subject sera at various time points to elucidate the half-life (t1/2) of NA-831 and GS-5734 in human serum.
Measure: Half-Life (t1/2) - Pharmacokinetic Assessment Time: 7 daysDescription: Monitoring of the levels of drugs in subject sera through various time points to elucidate the volume of distribution (Vd) of NA-831 and GS-5734 in human serum.
Measure: Volume of Distribution (Vd) - Pharmacokinetic Assessment Time: 7 daysDescription: Monitoring of the levels of drugs in subject sera through at various time points to elucidate clearance [CL] of NA-831 and GS-5734 in human serum.
Measure: Clearance [CL] - Pharmacokinetic Assessment Time: 7 days